154 related articles for article (PubMed ID: 20195683)
1. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Sakuma K; Hosoya Y; Arai W; Haruta H; Ui T; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Hyodo M; Nagai H; Yasuda Y; Shirasaka T
Int J Clin Oncol; 2010 Apr; 15(2):166-71. PubMed ID: 20195683
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H; Kanda M; Morita S; Taguri M; Nishikawa K; Shimada M; Muguruma K; Koeda K; Takahashi M; Nakamori M; Konno H; Tsuji A; Hosoya Y; Shirasaka T; Yamamitsu S; Sowa M; Kitajima M; Okajima M; Kobayashi M; Sakamoto J; Saji S; Hirakawa K
Int J Clin Oncol; 2017 Dec; 22(6):1052-1059. PubMed ID: 28667408
[TBL] [Abstract][Full Text] [Related]
4. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
[TBL] [Abstract][Full Text] [Related]
6. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Ohshima T; Yamada R; Hatori S; Kunisaki C; Makino T; Yamazaki Y; Suda T; Rino Y; Takanashi Y; Imada T
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1105-10. PubMed ID: 16912529
[TBL] [Abstract][Full Text] [Related]
7. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.
Iwasa S; Yamada Y; Fukagawa T; Eguchi Nakajima T; Kato K; Hamaguchi T; Morita S; Saka M; Katai H; Shimada Y
Gastric Cancer; 2011 Mar; 14(1):28-34. PubMed ID: 21327440
[TBL] [Abstract][Full Text] [Related]
8. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
9. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
[TBL] [Abstract][Full Text] [Related]
10. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim SJ; Kim YJ; Kim JH; Park DJ; Kim HH; Lee JS; Lee KW
Cancer Sci; 2013 Jan; 104(1):116-23. PubMed ID: 23066919
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
[TBL] [Abstract][Full Text] [Related]
12. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
14. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
[TBL] [Abstract][Full Text] [Related]
17. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
Chou WC; Chang CL; Liu KH; Hsu JT; Cheng WH; Hsu HC; Shen WC; Hung YS; Chen JS
World J Surg Oncol; 2013 Nov; 11():287. PubMed ID: 24180462
[TBL] [Abstract][Full Text] [Related]
18. Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Cho H; Konishi K; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Imada T
Gastric Cancer; 2003; 6 Suppl 1():24-7. PubMed ID: 12775016
[TBL] [Abstract][Full Text] [Related]
19. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
[TBL] [Abstract][Full Text] [Related]
20. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
Yoshimura K; Uehara K; Tojima Y; Kawai S; Mokuno Y; Maeda A; Kyokane T; Kobayashi S; Yoshioka Y; Nagino M
Trials; 2013 Jan; 14():17. PubMed ID: 23320901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
